SCYNEXIS Inc (NASDAQ: SCYX) rose 4.4% to $5.01 after the company disclosed that results from Phase 2 studies confirmed antifungal activity of oral SCY-078 in patients with Candida infections. The company also reported closing of a $15-million term loan with Solar Capital Ltd. Share volume was 2.8 million, triumphing over an all-day average of 728,000
